Co-Diagnostics and ReadyGo Collaborate to Evaluate Blood-Based Molecular Testing at the Point of Need, Starting with Ebola
Co-Diagnostics and ReadyGo begin feasibility work on blood-based use of the Co-Dx PCR platform, with Ebola as the first targeted application.
Rhea-AI Summary
Co-Diagnostics (CODX) and ReadyGo Diagnostics announced a collaboration to evaluate combining the Co-Dx PCR platform with ReadyGo’s GoCollect blood sample-preparation technology for point-of-need molecular testing, initially targeting decentralized Ebola virus detection and outbreak response.
The partners are conducting feasibility work to see if GoCollect-prepared capillary blood samples can be processed on the Co-Dx PCR platform as part of a streamlined, field-deployable workflow. Establishing blood as a compatible sample type could eventually enable testing for additional bloodborne pathogens such as HIV and hepatitis B and C, but compatibility, product development, and regulatory authorizations are still pending and commercial availability is uncertain.
Positive
- None.
Negative
- None.
News Explained
The collaboration remains in feasibility work: the Co-Dx PCR platform has not been FDA-cleared or authorized and is not yet available for sale, so the announcement does not establish a commercial blood-testing product.
Details
Market reaction after Ebola testing partnership: CODX -4.93%
Following this news, CODX has declined 4.93%, reflecting a moderate negative market reaction. Our momentum scanner has triggered 8 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $1.08. Trading volume is exceptionally heavy at 121.5x the average, suggesting significant selling pressure.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Confirmed Ebola cases
- 6,757 confirmed cases
- Democratic Republic of the Congo outbreak as of Sept. 7, 2026
- Ebola deaths
- 3,267 deaths
- Democratic Republic of the Congo outbreak as of Sept. 7, 2026
- Case fatality rate
- approximately 48%
- Democratic Republic of the Congo outbreak as of Sept. 7, 2026
- Affected health zones
- 61 health zones
- Across six provinces in the Democratic Republic of the Congo
Historical Context
-
Launched India cloud and mobile infrastructure supporting decentralized Co-Dx PCR clinical studies
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
pcr technical
bloodborne pathogens medical
plasma separation medical
case fatality rate medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Blood-based testing could open new markets for the Co-Dx® PCR platform, including HIV and hepatitis B and C
Co-Diagnostics and ReadyGo target decentralized Ebola detection as the first application of their collaboration
Combining GoCollect® sample preparation with Co-Dx PCR technology could bring blood-based molecular testing closer to patients
Company to hold in-person press conference and live webcast today at 10:30 a.m. ET
The companies are evaluating two potentially complementary technologies: the Co-Dx® PCR platform*, a point-of-need PCR technology; and GoCollect® by ReadyGo, a field sample-preparation system that prepares blood samples for molecular testing at the point of need. The collaboration will assess whether the technologies can operate together as part of a streamlined workflow that prepares the sample, detects the virus, and supports the outbreak response as one connected approach. The collaboration builds on Co-Dx's earlier proof-of-concept work testing an Ebola assay using plasma as a sample type.
"From the beginning, our objective has been to make molecular testing accessible to patients in settings with limited laboratory infrastructure," said Dwight Egan, Chief Executive Officer of Co-Diagnostics. "Preparing a blood sample for testing in those settings is an important part of that challenge, and ReadyGo brings technology that we believe could help us address it. This work with ReadyGo builds on our earlier work with plasma as we evaluate a practical blood-based testing workflow for the Co-Dx PCR platform. While Ebola is our initial focus, we believe the longer-term significance is the potential to expand the platform into additional applications, including HIV and hepatitis B and C. There are development and validation efforts ahead, but success could substantially broaden the range of diseases we can address and the commercial opportunity for the platform."
ReadyGo's GoCollect® technology is designed to prepare capillary blood samples for molecular testing through integrated sample-conditioning chemistry and plasma separation. Its collection chemistry is also intended to inactivate the virus at the point of collection, an important consideration for handling samples safely outside a laboratory. The companies are evaluating whether the resulting sample can be processed on the Co-Dx PCR platform, which is designed to bring molecular detection to decentralized settings where outbreaks occur and to synchronize results through Co-Dx cloud infrastructure. That compatibility has not yet been established and is the subject of the feasibility work now underway.
"We designed GoCollect for places where a laboratory isn't an option, where a sample either gets tested nearby or it doesn't get tested at all," said Ben Cobb, CEO of ReadyGo Diagnostics. "GoCollect takes sample collection and preparation into the field, and works seamlessly with platforms such as Co-Dx to create a complete sample-to-result molecular testing solution. Both technologies were designed around the same need, making high-quality molecular diagnostics practical outside conventional laboratory settings. This work will demonstrate how effectively they can operate together in the field."
Ebola remains a fast-moving and highly lethal public health threat. In the ongoing outbreak in the
Beyond Ebola, extending sample compatibility to blood could broaden the range of applications the Co-Dx PCR platform can address, including testing for bloodborne pathogens such as HIV and hepatitis B and C, a category swab-based sampling cannot reach. This category also represents substantially larger diagnostic markets than the Company's current menu. Each such application would require its own development, validation, and regulatory authorization. The Company believes blood compatibility could also create additional opportunities across infectious disease testing and public health monitoring and response.
The companies have begun feasibility work to evaluate the compatibility and workflow integration of the two technologies, and Co-Dx has taken delivery of ReadyGo materials and devices to support that evaluation. There can be no assurance that the evaluation will be successful or that it will result in a commercially available product.
Press Conference and Webcast:
Co-Dx will host a live press conference and webcast on Wednesday, September 16, 2026, at 10:30 a.m. ET to discuss the collaboration and more. A live webcast, together with a replay, will be available here, and the presentation will be posted to the Company's Investor Relations website.
*The Co-Dx PCR platform (including the PCR Home®, PCR Pro®, mobile app, and all associated tests) has not been cleared or authorized by the FDA, is subject to review by the FDA and/or other regulatory bodies, and is not yet available for sale.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
About ReadyGo Diagnostics Ltd.:
ReadyGo Diagnostics Ltd., based in Bath, United Kingdom, develops field sample-preparation technology, including its GoCollect® product line, designed to prepare samples for molecular testing at the point of need.
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will," "seeks," "anticipates," and similar expressions, or the negative of these terms. Forward-looking statements in this press release include, but are not limited to, statements regarding: the anticipated benefits of the Company's work with ReadyGo Diagnostics; the risk that ReadyGo's technology may not be compatible with the Co-Dx PCR platform or may not perform as anticipated; the risk that the companies' current evaluation activities may be modified, delayed or discontinued and may not lead to further development activities, a commercial agreement or a commercially available product; the ability of the combined technologies to enable decentralized Ebola detection and outbreak response; the expectation that extending sample compatibility to blood will broaden the applications of the Co-Dx PCR platform; and the results and timing of feasibility and compatibility evaluations. Such statements are subject to a number of risks and uncertainties, including, without limitation: risks that feasibility or compatibility studies may not produce successful or timely results; risks that the collaboration may be modified or terminated, or may not result in a commercially available product; risks related to the Company's and ReadyGo's ability to successfully integrate their respective technologies; risks related to regulatory review by regulatory authorities that would be required to achieve a successful commercial launch; risks related to the performance, reliability, and market acceptance of the Co-Dx PCR platform and other Co-Dx technologies; risks associated with dependence on third parties, suppliers, collaborators, and distribution partners; risks related to competition, technological change, and intellectual property protection; and other risks described from time to time in the Company's filings with the Securities and Exchange Commission ("SEC"). Actual results may differ materially from those expressed or implied in these forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements. A further description of risks and uncertainties can be found in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2026, and in its other filings with the SEC. The Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release, except as required by applicable law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-and-readygo-collaborate-to-evaluate-blood-based-molecular-testing-at-the-point-of-need-starting-with-ebola-302880383.html
SOURCE Co-Diagnostics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What specific technologies are being evaluated in the Co-Diagnostics–ReadyGo collaboration?
The collaboration evaluates two potentially complementary technologies: the Co-Dx PCR platform, a point-of-need PCR system, and GoCollect by ReadyGo, a field sample-preparation system that conditions and separates plasma from capillary blood for molecular testing. The work focuses on whether these can operate together as a connected sample-to-result workflow for decentralized testing.
Why are Co-Diagnostics and ReadyGo focusing first on Ebola detection?
The initial application is decentralized Ebola virus detection because Ebola remains a fast-moving, highly lethal public health threat, with an ongoing outbreak in the Democratic Republic of the Congo that the World Health Organization has described as the second-largest on record. The companies state that faster, closer-to-patient molecular testing could help shorten time to results in such rapidly spreading outbreaks.
What future applications do the companies see if blood compatibility is achieved?
The companies indicate that establishing blood as a compatible sample type could broaden the Co-Dx PCR platform’s use to bloodborne pathogens such as HIV and hepatitis B and C, which swab-based sampling cannot reach. Each new application would require its own development, validation, and regulatory authorization, and the companies also see potential in wider infectious disease testing and public health monitoring.
What is the current regulatory status of the Co-Dx PCR platform?
The Co-Dx PCR platform, including PCR Home, PCR Pro, the mobile app, and all associated tests, has not been cleared or authorized by the FDA, remains subject to FDA and/or other regulatory review, and is not yet available for sale.
Has compatibility between GoCollect and the Co-Dx PCR platform been established?
No. Compatibility and workflow integration are the subject of the feasibility work now underway, and there is no assurance that the evaluation will be successful or result in a commercially available product.
When and how will Co-Diagnostics discuss this collaboration with stakeholders?
Co-Diagnostics will host an in-person press conference and live webcast on Wednesday, September 16, 2026, at 10:30 a.m. ET to discuss the collaboration and related topics. A live webcast and replay will be available online, and the presentation will be posted to the company’s Investor Relations website.